NantCell, Inc.

Quick facts

Phase 1 pipeline

• Ad5 CEA Vaccine
  An adenoviral vector-based vaccine that delivers the CEA gene to stimulate immune responses against CEA-expressing cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• NantCell, Inc. portfolio CI brief
• NantCell, Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies